Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. - Wikidata - wikimedia - TriplyDB

Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.

Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.

http://www.wikidata.org/entity/Q33915990

about

The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies Monoclonal antibodies in acute lymphoblastic leukemia Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates.Novel antibody therapy in acute lymphoblastic leukemia.Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells.Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia.Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia.Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia Immunotherapy approaches to treat adult acute lymphoblastic leukemia.Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.Emerging biological therapies to treat acute lymphoblastic leukemia.Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.Advances in adult acute lymphoblastic leukemia therapy.Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.

P2860

Q26783425-5187BA88-D086-469B-BF05-46C8109C7817 Q26828511-66EAAE84-F371-4F4F-93C7-1129ED97BE30 Q27022540-60F54312-80C0-4885-B126-42E536F65A07 Q36055238-7A1E60AF-D0F3-437E-A296-607A084FA828 Q36979140-6694CA2F-466D-4068-8326-13BA09A938F2 Q38095113-0B933EEF-E5CE-4D12-AFE5-E74931A75E85 Q38195539-9D47A0B4-B24B-466C-A94C-10AE44CF3E52 Q38312596-6BD556DF-6854-4DD2-8256-E9C780BA2119 Q38379829-5CCCFC3F-BD95-4DE7-A4F6-1A8027117950 Q38428357-383A68A5-1347-4C18-B41B-BF1271F36628 Q38434000-B30B3451-8D86-4C58-B1BE-AF5560A0E7E8 Q38665500-0F2108C4-11D2-465F-80BE-72B1F454FC3B Q38701163-433679AD-7E1E-40D4-BF1F-2446B6CBD7ED Q38787405-2E563E1B-9555-481A-BF8F-74A1FD885F65 Q38813978-09804363-4B70-4CAE-9112-04304C9C0D96 Q38984055-A04EC058-1612-4B1A-87D6-DBB4BFD223D8 Q39002036-29277BBF-0449-4A33-88AB-4BBB7D97753A Q39212390-2C7B18BA-D48C-4E95-B6B8-8652D00823A5 Q39459190-95818995-B5ED-416B-98CE-DDACFC3C1E27 Q49276207-08EFE057-1BDC-40F5-88B0-239F72E652E8

P2860

Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.

http://www.wikidata.org/entity/Q33915990

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Feasibility of allografting in ...... py with inotuzumab ozogamicin.

@ast

Feasibility of allografting in ...... py with inotuzumab ozogamicin.

@en

type

label

Feasibility of allografting in ...... py with inotuzumab ozogamicin.

@ast

Feasibility of allografting in ...... py with inotuzumab ozogamicin.

@en

prefLabel

Feasibility of allografting in ...... py with inotuzumab ozogamicin.

@ast

Feasibility of allografting in ...... py with inotuzumab ozogamicin.

@en

P1433

Q33915990-11B84469-61DD-4EC2-B4BE-38A63D894616

P1476

Q33915990-1A3C1EF8-1129-44D3-B688-1ABB6ED65906

P2093

Q33915990-106ABDB3-6DA8-43E8-9DFD-099F3AD3B879

Q33915990-2445C95E-B6D0-4CC6-B3DC-A20481E28F0F

Q33915990-453C11A2-C05E-4EE9-9B30-B0A0903B7650

Q33915990-658C3256-2FF6-48E1-A1DE-F511E62274DA

Q33915990-7BE70CE6-19EE-4F6D-A352-F46567B3BB92

Q33915990-A8C9446E-79D9-4F27-891F-ABE7BD6605CF

Q33915990-B9623272-FBEF-4E5D-BBF9-2D014C8B0FD4

Q33915990-BD02E268-9299-46CE-8D87-FE121AA57CD8

P2860

Q33915990-06D5526B-16E9-4959-820C-067B8576C911

Q33915990-1897F243-7394-4AD7-9BCA-CA0298990320

Q33915990-1A167086-3719-4D2C-9C66-78154D62A099

Q33915990-1CE99AAC-480B-4253-9B7C-A33459304AB3

Q33915990-36DF076C-5129-4D29-847E-9E68B43C86FA

Q33915990-3B7A8984-AC07-4BA0-A302-93498C3F8DD2

Q33915990-4A8A4B0D-56F5-4692-9A5A-D86F17D36F30

Q33915990-5155DB8B-CDCD-45AC-8446-E2E3524F1E72

Q33915990-5437945D-3789-4633-9DDF-672DEB2669B1

Q33915990-73B3BE31-E7FD-455B-91D0-B19FD652463B

P304

Q33915990-72A51178-0620-425A-BA65-762D447A86C6

P31

Q33915990-EAD5E065-F215-4E45-B13F-45D9916B6770

P356

Q33915990-21D9A466-F441-4F6F-A9F0-037DF0333334

P407

Q33915990-F554F01F-80BE-4FB9-AEF3-6ACFD7CC5D91

P433

Q33915990-B401E667-9C5E-4B83-93C8-C8F2B562615B

P478

Q33915990-3375B53B-09EE-441A-A1F3-7E812F395562

P50

Q33915990-16B3BCAC-49B4-4400-97C9-65E010E03177

Q33915990-5A804FEA-A767-41A7-8175-F77C17C75D98

Q33915990-CB6960A2-9878-4C61-8392-D462CE649B43

P577

Q33915990-74BF438B-8228-464C-BF0E-4223B933F03E

P698

Q33915990-0F0F3667-D1DD-4197-AAAF-5237645BA63D

P921

Q33915990-751252CD-97C1-427C-95FC-F93040B0BD20

P932

Q33915990-260E3377-C484-47C6-85B1-7EB2F0CDD2C9

P356

J.CLML.2012.12.003

P1433

Clinical Lymphoma, Myeloma & Leukemia

P1476

Feasibility of allografting in ...... py with inotuzumab ozogamicin.

@en

P2093

Deborah Thomas

http://www.w3.org/2001/XMLSchema#string

Kaci Wilhelm

http://www.w3.org/2001/XMLSchema#string

Laura Worth

http://www.w3.org/2001/XMLSchema#string

Marcos de Lima

http://www.w3.org/2001/XMLSchema#string

Mark Brandt

http://www.w3.org/2001/XMLSchema#string

Partow Kebriaei

http://www.w3.org/2001/XMLSchema#string

Richard E Champlin

http://www.w3.org/2001/XMLSchema#string

Stefan Ciurea

http://www.w3.org/2001/XMLSchema#string

P2860

Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.

Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research.

Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease).

Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.

P304

296-301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLML.2012.12.003

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

P577

2013-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23313065

http://www.w3.org/2001/XMLSchema#string

P921

P932

4102410

http://www.w3.org/2001/XMLSchema#string